Xvivo Perfusion AB — Cyborg Score 7/10

Strong
Medical Technology - Organ Transplant Preservation & Perfusion Systems

Strategic Profile

In lung transplantation, XVIVO markets PERFADEX Plus for cold preservation and XPS with STEEN Solution for machine perfusion, where it is the global leader. For liver transplantation, XVIVO markets Liver Assist, the leading perfusion technology in Europe. XVIVO aims to be the fastest growing company in kidney perfusion.

Cyborg Score Rationale

XVIVO commands dominant market positions in key organ preservation niches (90% lung market share via PERFADEX Plus), operates in a structurally attractive medtech segment with high switching costs and recurring consumables revenue, and demonstrates proven clinical efficacy with strong regulatory validation across multiple products.

Top Insights

  • PERFADEX® Plus is a patented solution for flushing and static cold storage of lungs, used by more than 90% of transplantation clinics globally
  • Liver Assist, celebrating its 25th anniversary in 2024, is the most scientifically validated liver perfusion technology, featured in multiple randomized control trials, and enables extended liver perfusion times of up to 20 hours
  • In heart transplantation, XVIVO is introducing a pioneering preservation technology expected to receive CE marking in the first half of 2025, enabling a European launch
  • Kidneys are the most commonly transplanted organ, with about 113,000 procedures in 2023, including 28,000 in the U.S.

Named Competitors

  • Organ Preservation Technologies — Normothermic organ perfusion systems
  • Surgical Devices — Diversified medical device manufacturer
  • Patient Monitoring — Cloud-connected medical devices

Recent Developments

  • (March 2025) Heart transplant preservation technology approaching CE marking for European launch
  • (2024) Liver Assist clinically validated in Lancet study demonstrating 20-hour perfusion capability
  • (2024) Kidney Assist Transport acceleration continuing across major markets with strong clinical evidence

Open the full interactive Xvivo Perfusion AB report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →